UNASSIGNED: Diet and nutritional factors have emerged as possible interventions for @entity29 ( @entity29 ), which are characterised by chronic uncontrolled @entity32 of the intestinal mucosa. Microalgal species are a promising source of n-3 @entity5204 and derived @entity3227 , which are lipid mediators with a key role in the resolution of @entity32 . The aim of the present study was to investigate the effects of an @entity3228 -containing lyophilised biomass from Chlamydomonas debaryana on a recurrent @entity10776 ( @entity10776 )-induced @entity1960 @entity19 model. Moderate chronic @entity32 of the colon was induced in BALB/c @entity19 by weekly intracolonic instillations of low dose of @entity10776 . Administration of the lyophilised microalgal biomass started 2 weeks before @entity1960 induction and was continued throughout @entity1960 development. @entity19 were killed 48 h after the last @entity10776 challenge. Oral administration of the microalgal biomass reduced @entity10776 -induced @entity32 , evidenced by an inhibition of body weight loss, an improvement in colon morphology and a decrease in pro-inflammatory cytokines @entity637 , @entity635 , @entity777 and @entity636 . This product also down-regulated colonic expressions of inducible @entity842 , @entity1996 and NF-kB, as well as increased @entity3229 -y. In addition, lyophilised microalgal biomass up-regulated the expressions of the antioxidant transcription factor nuclear factor E2-related factor 2 and the target gene @entity10183 . This study describes for the first time the prophylactic effects of an @entity3228 -containing lyophilised microalgae biomass from C. debaryana in the acute phase of a recurrent @entity10776 -induced @entity1960 model in @entity19 . These findings suggest the potential use of this microalga, or derived @entity3227 , as a nutraceutical in the treatment of @entity29 .

Anti-inflammatory effects of an XXXX -containing lyophilised biomass from a microalga in a @entity19 recurrent @entity1960 model.

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'intestinal inflammation'] @entity5204 :: ('CHEBI:26208', 'Chemical') :: ['PUFA'] @entity3229 :: ('19013(Tax:10090)', 'Gene') :: ['PPAR'] @entity10183 :: ('15368(Tax:10090)', 'Gene') :: ['heme oxygenase 1'] @entity1996 :: ('19225(Tax:10090)', 'Gene') :: ['cyclo-oxygenase 2'] @entity19 :: ('10090', 'Species') :: ['mice', 'Mice'] @entity635 :: ('16176(Tax:10090)', 'Gene') :: ['IL-1b'] @entity636 :: ('16171(Tax:10090)', 'Gene') :: ['IL-17'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel diseases', 'IBD'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis'] @entity777 :: ('16193(Tax:10090)', 'Gene') :: ['IL-6'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity3228 :: ('CHEBI:61121', 'Chemical') :: ['oxylipin'] @entity3227 :: ('MESH:D054883', 'Chemical') :: ['oxylipins'] @entity10776 :: ('CHEBI:53063', 'Chemical') :: ['2,4,6-trinitrobenzenesulfonic acid', 'TNBS'] @entity637 :: ('21926(Tax:10090)', 'Gene') :: ['TNF-a']
@entity3228 :: (CHEBI:61121,Chemical) :: ['oxylipin']
